Abstract
The case of generic imatinib demonstrates several potential barriers to effective generic price competition for specialty prescription drugs, including fewer market entrants, smaller-than-expected price reductions, shifts in prescribing toward more expensive brand-name treatments, and limited uptake of the generic product.
Keywords:
Access To Care; Cost of Health Care; Health Spending; Pharmaceuticals.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Antineoplastic Agents / economics
-
Antineoplastic Agents / therapeutic use
-
Cost Savings*
-
Dasatinib / economics
-
Dasatinib / therapeutic use*
-
Databases, Factual
-
Drug Costs*
-
Drugs, Generic / economics*
-
Drugs, Generic / pharmacology
-
Drugs, Generic / supply & distribution
-
Economic Competition*
-
Female
-
Humans
-
Imatinib Mesylate / economics
-
Imatinib Mesylate / therapeutic use
-
Insurance, Pharmaceutical Services / economics
-
Insurance, Pharmaceutical Services / statistics & numerical data
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Male
-
Marketing
-
Outpatients / statistics & numerical data
-
Retrospective Studies
-
United States
Substances
-
Antineoplastic Agents
-
Drugs, Generic
-
Imatinib Mesylate
-
Dasatinib